[
  {
    "ts": null,
    "headline": "January jobs data, Alphabet and Amazon earnings, more Warsh fallout: What to watch this week",
    "summary": "Crucial labor market data, more earnings from Big Tech giants, and continued discussion over where Kevin Warsh may lead the central bank should set the agenda in the week ahead.",
    "url": "https://finnhub.io/api/news?id=22a75c6698ef0c76639591b1eb45c7cf7117cb7863e10896a6b1489fadf887dd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769950043,
      "headline": "January jobs data, Alphabet and Amazon earnings, more Warsh fallout: What to watch this week",
      "id": 138323726,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Crucial labor market data, more earnings from Big Tech giants, and continued discussion over where Kevin Warsh may lead the central bank should set the agenda in the week ahead.",
      "url": "https://finnhub.io/api/news?id=22a75c6698ef0c76639591b1eb45c7cf7117cb7863e10896a6b1489fadf887dd"
    }
  },
  {
    "ts": null,
    "headline": "Is Biogen (BIIB) Pricing Reflect Recent 1 Year Rebound And Long Term Weakness?",
    "summary": "If you are wondering whether Biogen's current share price gives you good value for the risk you are taking, you are not alone. Over the last year the stock returned 25.0%. The 3 year and 5 year returns were declines of 36.6% and 32.1%, alongside a 7 day return of 4.8%, and a 30 day and year to date return of 1.2%. Recent attention on Biogen has centered on its position in pharmaceuticals and biotech, with investors weighing how its product portfolio and pipeline might justify the current...",
    "url": "https://finnhub.io/api/news?id=a43dcd0473639435ae8938491c2d9db6dec77aeae9e7b4cbef77b40490646cb2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769947893,
      "headline": "Is Biogen (BIIB) Pricing Reflect Recent 1 Year Rebound And Long Term Weakness?",
      "id": 138323902,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "If you are wondering whether Biogen's current share price gives you good value for the risk you are taking, you are not alone. Over the last year the stock returned 25.0%. The 3 year and 5 year returns were declines of 36.6% and 32.1%, alongside a 7 day return of 4.8%, and a 30 day and year to date return of 1.2%. Recent attention on Biogen has centered on its position in pharmaceuticals and biotech, with investors weighing how its product portfolio and pipeline might justify the current...",
      "url": "https://finnhub.io/api/news?id=a43dcd0473639435ae8938491c2d9db6dec77aeae9e7b4cbef77b40490646cb2"
    }
  },
  {
    "ts": null,
    "headline": "Biogen’s Litifilimab Milestone Puts Spotlight On Valuation And Growth Prospects",
    "summary": "Biogen's investigational drug litifilimab has received FDA Breakthrough Therapy Designation for treating cutaneous lupus erythematosus. The designation highlights litifilimab's potential to address an unmet need in a chronic autoimmune skin condition with limited treatment options. This represents a significant milestone in Biogen's drug pipeline that could speed up development timelines for this program. For investors watching Biogen, ticker NasdaqGS:BIIB, this update on litifilimab adds a...",
    "url": "https://finnhub.io/api/news?id=c0dcb729b17c190b45d90cf6c05de5d6ac299715a7afd714fc4bfebcffb423ce",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769905128,
      "headline": "Biogen’s Litifilimab Milestone Puts Spotlight On Valuation And Growth Prospects",
      "id": 138320751,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen's investigational drug litifilimab has received FDA Breakthrough Therapy Designation for treating cutaneous lupus erythematosus. The designation highlights litifilimab's potential to address an unmet need in a chronic autoimmune skin condition with limited treatment options. This represents a significant milestone in Biogen's drug pipeline that could speed up development timelines for this program. For investors watching Biogen, ticker NasdaqGS:BIIB, this update on litifilimab adds a...",
      "url": "https://finnhub.io/api/news?id=c0dcb729b17c190b45d90cf6c05de5d6ac299715a7afd714fc4bfebcffb423ce"
    }
  }
]